

Irina A Leneva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6106684/publications.pdf>

Version: 2024-02-01

13
papers

356
citations

1684188

5
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

734
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2022, 98, 648-656.	1.0	0
2	The study of neuraminidase immunity in protection against secondary bacterial pneumonia induced by <i>S. aureus</i> after influenza infection in mice. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 97, 564-577.	1.0	0
3	Local antiviral activity of the drug «Thymogen», nasal dosed spray, against SARS-CoV-2 coronavirus &in vitro. Antibiotiki I Khimioterapiya, 2021, 66, 11-16.	0.6	1
4	Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses, 2021, 13, 1665.	3.3	17
5	Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir-3 &in vitro study. Antibiotiki I Khimioterapiya, 2021, 66, 4-10.	0.6	4
6	Efficacy of (R)-6-Adamantane-Derivatives of 1,3-Oxazinan-2-One and Piperidine-2,4-Dione in The Treatment of Mice Infected by the A/California/04/2009 influenza Virus. Acta Naturae, 2021, 13, 116-125.	1.7	5
7	Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. Terapevticheskii Arkhiv, 2021, 93, 1306-1315.	0.8	1
8	Antioxidant Potential of Antiviral Drug Umifenovir. Molecules, 2020, 25, 1577.	3.8	35
9	Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study. Journal of Medical Virology, 2019, 91, 588-597.	5.0	23
10	Activity of compounds containing echinochrome A against herpes simplex virus type 2 &in vitro and &in vivo. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2019, , 56-64.	1.0	2
11	The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2019, , 30-39.	1.0	2
12	A novel influenza virus neuraminidase inhibitor AV5027. Antiviral Research, 2013, 100, 698-708.	4.1	18
13	Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Research, 2009, 81, 132-140.	4.1	244